{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018333","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.035365+00:00","generated_at":"2026-05-16T01:21:06.146924+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia","bullets":["AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.","QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.","CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.","Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018333","json":"https://secwatch.observer/filing/0001104659-26-018333.json","markdown":"https://secwatch.observer/filing/0001104659-26-018333.md","text":"https://secwatch.observer/filing/0001104659-26-018333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/0001104659-26-018333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/tm267017d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:21:06.146924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}